A new biomarker may be able to differentiate between benign and cancerous lung nodules. The biomarker—a panel of the expression levels of three microRNAs from a sample of sputum--was able to decipher between noncancerous nodules and early-stage lung cancer most of the time.
An investigational cancer immunotherapy known as MPDL3280A (anti-PDL1) is receiving a breakthrough therapy designation from the US Food and Drug Administration (FDA) for treating non-small cell lung cancer (NSCLC).
Scientists from The Institute of Cancer Research in London identified a gene which may contribute to testicular cancer treatment resistance.
A 72-year-old man is found to have a bladder mass. After further evaluation, a biopsy is performed. What is your diagnosis?
A new targeted therapy is being greenlighted for treating patients with polycythemia vera (PV) who have failed or could not tolerate hydroxyurea. The US Food and Drug Administration (FDA) on December 4, 2014 approved ruxolitinib (Jakafi), which inhibits Janus Associated Kinase (JAK) 1 and 2.
IL-13 has been identified as an autocrine factor for cutaneous T-cell lymphomas (CTCL) and its receptors may be novel tumor markers for the disease, serving as potential therapeutic targets, results of a study published recently in Blood showed.
Japanese drug maker Eisai announced that the multiple kinase inhibitor lenvatinib, alone and in combination with everolimus, has been shown to prolong progression-free survival (PFS) in patients with unresectable advanced or metastatic renal cell carcinoma (mRCC).
A multicenter, double-blind, placebo-controlled, phase III vaccine trial is now underway for post-resection melanoma patients with a high risk of recurrence.
Because of the high mutation rate in melanoma cells, cancer drugs have been developed to help target these signaling pathways that stimulate such rapid growth. While many of these drugs have proven to be successful, resistance to these same drugs can also occur.
When it comes to cutaneous malignant melanoma (CMM), BRAF V600E is a common mutation found in approximately 50% of cases. Currently, BRAF mutations are detected by using DNA tests, but there may be an alternative assay that's less expensive, requires less tissue, more efficient, and thought to be more sensitive.
A 67-year-old man presents with hematuria and a kidney mass found on imaging. After further evaluation, a biopsy is performed. What is your diagnosis?
Of the 39 advanced gastric cancer patients treated with the immunotherapy antibody, pembrolizumab (Keytruda, Merck), 22.2% had an objective response. The median time to response was 8 weeks and the median progression-free survival (PFS) was 1.9 months
The PD-1 inhibitor nivolumab increased progression-free and overall survival compared with chemo in patients with previously untreated metastatic melanoma.
No difference in anxiety was found among patients with non-Hodgkin lymphoma who were assigned to maintenance rituximab compared with those patients who were assigned to rituximab re-treatment upon disease progression, results of a recent study show.
Researchers at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, have discovered a protein that could help treat certain lymphomas, including those resistant to therapy.